UK: In the age of AMR, does a nationalised drug company make sense? The case for and against

  03 July 2019

A UK economist has come out saying that pharma companies are dragging their heels in the fight against superbugs and the only resolution would be creating a state-run drug company. Could he be right, or is international support and funding for a competitive marketplace the best solution to developing new lifesaving antibiotics? The editorial team put forward the arguments for and against a national drug company.

Further reading: Borderless
Author(s): Allie Nawrat and Chloe Kent
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!